Current and Emerging CAR T-Cell Therapies in Cancer Care

Download All
Hear from the experts on how the latest clinical data inform the use of CAR T-cell therapies across hematologic malignancies. Review their insights with an on-demand webcast adapted from a live webinar, along with downloadable slidesets, 2 expert commentaries, and a podcast.
person default
Caron A. Jacobson, MD
Jae H. Park, MD
Noopur Raje, MD

Downloadable Slidesets

Download this slideset for expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.

person default Caron A. Jacobson, MD Released: June 16, 2021

Download this slideset for expert perspectives on optimal strategies in the use of CAR T-cell therapy for patients with multiple myeloma.

Noopur Raje, MD Released: June 16, 2021

Download this slideset for expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with ALL, as well as a discussion of key toxicities associated with CAR T-cell therapy.

Jae H. Park, MD Released: June 16, 2021

ClinicalThought

The approval of the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel provides another treatment option for some patients with relapsed/refractory multiple myeloma. Review this expert commentary on how to incorporate this therapeutic agent into your practice.

Noopur Raje, MD Released: June 2, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue